NewCrunchbase News · 13 Nov 2026 · Collaborations & pilots
Johnson & Johnson Innovation co-leads USD 100 million Series C of Delix Therapeutics
Delix Therapeutics, a biotech in Bedford, Massachusetts, raised a USD 100 million Series C. Johnson & Johnson Innovation (JJDC) co-led the round with SV Health Investors' Dementia Discovery Fund. Delix develops optimised, psychedelic-derived compounds for psychiatric disorders.
Why it matters: Pharma CVCs co-lead with specialist funds in therapy areas where they want early access before clinical results.